ArticleACS omega2025
Synthesis of Platinum Nanoparticles by Pulsed Laser Ablation with an Excimer KrF Laser in Deep Eutectic Solvents.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This work reports for the first time the fabrication of metallic nanoparticles from platinum material (Pt-NPs) implying pulsed laser ablation in choline chloride-ethylene glycol deep eutectic solvent (DES) as well as in their mixtures with ethanol in a 1:3 ratio as liquid media. KrF excimer laser (λ = 248 nm) has been used as an irradiation source. The Pt target is placed in a Teflon pad on the bottom of a beaker and immersed in the corresponding liquid. The created Pt-NPs by pulsed laser ablation are dispersed in the surrounding medium, forming a colloid with it, and are characterized by the detailed methods described. A synergistic effect is achieved by combining the nontoxicity of the liquid and the biocompatibility of the Pt-NPs for the fabrication of very small, nonaggregated NPs, applicable, also, in the medical field. The peculiarities of the liquid do not allow the production parameters to be varied in wide ranges. The investigation of the Pt-NPs' optical characteristics by UV/vis spectroscopy showed the existence of three bands. The origins of two of the bands are presumably due to interband transition and plasmonic absorption, respectively. The origin of the third band needs further in-depth investigation. The morphological properties were studied through high-resolution scanning transmission electron microscopy (HR-STEM). The minimum value of the mean size of 2.2 nm is achieved at 7 Hz RR and 40 min ablation time when the pure mixture of choline chloride-ethylene glycol, denoted as ILEG, is used. In support, the obtained Pt-NPs were analyzed by direct analysis in real time mass spectrometry (DART-MS) to demonstrate their existence in the colloidal solution. The face-centered cubic (FCC) phase for the Pt-NPs with the predominant orientation of the (220) crystalline plane was determined by X-ray diffraction (XRD). FTIR and Raman spectroscopy measurements did not show the existence of additional bonds between pure ILEG and Pt-NPs. One application of the synthesized NPs was illustrated by the increased sensitivity of detecting methylene blue through the surface-enhanced Raman spectroscopy (SERS) method.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.